^
    Back
    Association details:
    Biomarker:MDC1 mutation
    Cancer:Melanoma
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.

    Published date:
    05/19/2021
    Excerpt:
    Eligible participants were adult pts (aged 18 to 75) with histologically confirmed unresectable stage or distant metastatic acral melanoma….Pts received camrelizumab at 200mg intravenous infusion every 2 weeks, in combination with apatinib 250 mg orally once a day....all of the 4pts with MDC1 gene mutation got tumor shrink and 2 got PR.
    DOI:
    10.1200/JCO.2021.39.15_suppl.9539
    Trial ID:
    SHR-1210-APTN-IIT-MM